Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Raw Materials (2016 - 2025)

Historic Raw Materials for Orthofix Medical (OFIX) over the last 15 years, with Q3 2025 value amounting to $24.8 million.

  • Orthofix Medical's Raw Materials fell 996.22% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year decrease of 996.22%. This contributed to the annual value of $27.2 million for FY2024, which is 426.21% down from last year.
  • As of Q3 2025, Orthofix Medical's Raw Materials stood at $24.8 million, which was down 996.22% from $26.6 million recorded in Q2 2025.
  • Over the past 5 years, Orthofix Medical's Raw Materials peaked at $30.9 million during Q1 2024, and registered a low of $8.0 million during Q3 2021.
  • Moreover, its 5-year median value for Raw Materials was $24.8 million (2025), whereas its average is $20.9 million.
  • Per our database at Business Quant, Orthofix Medical's Raw Materials surged by 11910.66% in 2022 and then plummeted by 1550.01% in 2025.
  • Quarter analysis of 5 years shows Orthofix Medical's Raw Materials stood at $9.6 million in 2021, then surged by 77.65% to $17.0 million in 2022, then surged by 66.66% to $28.4 million in 2023, then dropped by 4.26% to $27.2 million in 2024, then decreased by 8.82% to $24.8 million in 2025.
  • Its Raw Materials stands at $24.8 million for Q3 2025, versus $26.6 million for Q2 2025 and $26.1 million for Q1 2025.